Imatinib
Adjuvant Study 2 (SSG XVIII)
Novartis · Phase 3 · Completed · Enrollment 400
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Imatinib 400 mg for 36 months | resected high-risk KIT positive GIST | 400 mg | ITT | imatinib for 12 months | recurrence-free survival hazard ratio, 36 vs 12 months: 0.46 HR, median follow up 42 monthsoverall survival hazard ratio, 36 vs 12 months: 0.45 HR, median follow up 48 months |